Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.